EP Wealth Advisors LLC Increases Stake in Danaher Corporation $DHR

EP Wealth Advisors LLC raised its position in Danaher Corporation (NYSE:DHR) by 0.8% during the first quarter, according to its most recent filing with the SEC. The institutional investor owned 27,491 shares of the conglomerate’s stock after purchasing an additional 216 shares during the period. EP Wealth Advisors LLC’s holdings in Danaher were worth $5,636,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its holdings in Danaher by 0.4% in the 1st quarter. Vanguard Group Inc. now owns 59,981,088 shares of the conglomerate’s stock valued at $12,296,123,000 after purchasing an additional 230,966 shares in the last quarter. Price T Rowe Associates Inc. MD increased its stake in shares of Danaher by 3.2% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 19,592,211 shares of the conglomerate’s stock worth $4,016,404,000 after acquiring an additional 612,154 shares during the last quarter. Bank of New York Mellon Corp increased its stake in shares of Danaher by 2.3% in the 1st quarter. Bank of New York Mellon Corp now owns 8,783,485 shares of the conglomerate’s stock worth $1,800,614,000 after acquiring an additional 194,466 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Danaher by 11.4% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,677,032 shares of the conglomerate’s stock worth $1,303,163,000 after acquiring an additional 579,046 shares during the last quarter. Finally, Invesco Ltd. increased its stake in shares of Danaher by 44.5% in the 1st quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate’s stock worth $965,259,000 after acquiring an additional 1,450,703 shares during the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Insider Activity

In related news, Director Teri List sold 2,778 shares of the firm’s stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $211.06, for a total transaction of $586,324.68. Following the completion of the sale, the director directly owned 20,751 shares of the company’s stock, valued at approximately $4,379,706.06. This trade represents a 11.81% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 11.20% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have issued reports on DHR shares. Evercore ISI cut their target price on Danaher from $230.00 to $226.00 and set an “outperform” rating for the company in a research note on Tuesday, July 8th. Guggenheim reaffirmed a “buy” rating and issued a $250.00 target price on shares of Danaher in a research note on Wednesday, July 23rd. Barclays reaffirmed an “overweight” rating and issued a $225.00 target price (up from $215.00) on shares of Danaher in a research note on Tuesday, June 24th. Wells Fargo & Company cut their target price on Danaher from $210.00 to $205.00 and set an “equal weight” rating for the company in a research note on Wednesday, July 23rd. Finally, Wall Street Zen raised Danaher from a “hold” rating to a “buy” rating in a research note on Friday, June 27th. Seventeen research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, Danaher presently has an average rating of “Moderate Buy” and an average target price of $247.61.

Danaher Stock Down 1.0%

Shares of NYSE:DHR opened at $203.80 on Wednesday. The business has a 50-day moving average price of $201.97 and a 200 day moving average price of $199.49. The company has a current ratio of 1.62, a quick ratio of 1.22 and a debt-to-equity ratio of 0.32. The company has a market capitalization of $145.93 billion, a price-to-earnings ratio of 43.36, a PEG ratio of 2.87 and a beta of 0.75. Danaher Corporation has a 12-month low of $171.00 and a 12-month high of $279.90.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.64 by $0.16. The firm had revenue of $5.94 billion during the quarter, compared to the consensus estimate of $5.83 billion. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The company’s quarterly revenue was up 3.4% on a year-over-year basis. During the same period last year, the company earned $1.72 EPS. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Sell-side analysts expect that Danaher Corporation will post 7.63 EPS for the current year.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.